Article | August 23, 2022

Is Life Sciences Ready For Post-Pandemic Transformation?

Source: Merative

By Lorraine Marchand


The pandemic sparked the race to develop a COVID-19 vaccine. It also catalyzed new approaches to clinical trials and commercialization. Whether companies started to implement decentralized trials technology, explore external control arm studies or discover new sources and applications of real-world data (RWD), I hope the march toward innovative improvements to get therapies – and vaccines for evolving diseases – to patients safely and quickly will continue. There is no turning back to the way things used to be. The future is here, and we need to embrace it.


Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.

Subscribe to Clinical Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Clinical Leader